Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV.
Identifieur interne : 002B60 ( PubMed/Corpus ); précédent : 002B59; suivant : 002B61Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV.
Auteurs : John T-A Hsu ; Chih-Jung Kuo ; Hsing-Pang Hsieh ; Yeau-Ching Wang ; Kuo-Kuei Huang ; Coney P-C Lin ; Ping-Fang Huang ; Xin Chen ; Po-Huang LiangSource :
- FEBS letters [ 0014-5793 ] ; 2004.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Viral Proteins.
- chemical , chemistry : Metals, Protease Inhibitors.
- chemical , pharmacology : Protease Inhibitors.
- chemical : Cysteine Endopeptidases, Endopeptidases.
- enzymology : SARS Virus.
- Amino Acid Sequence, Animals, Chlorocebus aethiops, Molecular Sequence Data, Vero Cells.
Abstract
3C-like (3CL) protease is essential for the life cycle of severe acute respiratory syndrome-coronavirus (SARS-CoV) and therefore represents a key anti-viral target. A compound library consisting of 960 commercially available drugs and biologically active substances was screened for inhibition of SARS-CoV 3CL protease. Potent inhibition was achieved using the mercury-containing compounds thimerosal and phenylmercuric acetate, as well as hexachlorophene. As well, 1-10 microM of each compound inhibited viral replication in Vero E6 cell culture. Detailed mechanism studies using a fluorescence-based protease assay demonstrated that the three compounds acted as competitive inhibitors (Ki=0.7, 2.4, and 13.7 microM for phenylmercuric acetate, thimerosal, and hexachlorophene, respectively). A panel of metal ions including Zn2+ and its conjugates were then evaluated for their anti-3CL protease activities. Inhibition was more pronounced using a zinc-conjugated compound (1-hydroxypyridine-2-thione zinc; Ki=0.17 microM) than using the ion alone (Ki=1.1 microM).
DOI: 10.1016/j.febslet.2004.08.015
PubMed: 15358550
Links to Exploration step
pubmed:15358550Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV.</title>
<author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T-A" last="Hsu">John T-A Hsu</name>
<affiliation><nlm:affiliation>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, National Defense Medical Center, Taipei 115, Taiwan, ROC.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kuo, Chih Jung" sort="Kuo, Chih Jung" uniqKey="Kuo C" first="Chih-Jung" last="Kuo">Chih-Jung Kuo</name>
</author>
<author><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name>
</author>
<author><name sortKey="Wang, Yeau Ching" sort="Wang, Yeau Ching" uniqKey="Wang Y" first="Yeau-Ching" last="Wang">Yeau-Ching Wang</name>
</author>
<author><name sortKey="Huang, Kuo Kuei" sort="Huang, Kuo Kuei" uniqKey="Huang K" first="Kuo-Kuei" last="Huang">Kuo-Kuei Huang</name>
</author>
<author><name sortKey="Lin, Coney P C" sort="Lin, Coney P C" uniqKey="Lin C" first="Coney P-C" last="Lin">Coney P-C Lin</name>
</author>
<author><name sortKey="Huang, Ping Fang" sort="Huang, Ping Fang" uniqKey="Huang P" first="Ping-Fang" last="Huang">Ping-Fang Huang</name>
</author>
<author><name sortKey="Chen, Xin" sort="Chen, Xin" uniqKey="Chen X" first="Xin" last="Chen">Xin Chen</name>
</author>
<author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15358550</idno>
<idno type="pmid">15358550</idno>
<idno type="doi">10.1016/j.febslet.2004.08.015</idno>
<idno type="wicri:Area/PubMed/Corpus">002B60</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B60</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV.</title>
<author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T-A" last="Hsu">John T-A Hsu</name>
<affiliation><nlm:affiliation>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, National Defense Medical Center, Taipei 115, Taiwan, ROC.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kuo, Chih Jung" sort="Kuo, Chih Jung" uniqKey="Kuo C" first="Chih-Jung" last="Kuo">Chih-Jung Kuo</name>
</author>
<author><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name>
</author>
<author><name sortKey="Wang, Yeau Ching" sort="Wang, Yeau Ching" uniqKey="Wang Y" first="Yeau-Ching" last="Wang">Yeau-Ching Wang</name>
</author>
<author><name sortKey="Huang, Kuo Kuei" sort="Huang, Kuo Kuei" uniqKey="Huang K" first="Kuo-Kuei" last="Huang">Kuo-Kuei Huang</name>
</author>
<author><name sortKey="Lin, Coney P C" sort="Lin, Coney P C" uniqKey="Lin C" first="Coney P-C" last="Lin">Coney P-C Lin</name>
</author>
<author><name sortKey="Huang, Ping Fang" sort="Huang, Ping Fang" uniqKey="Huang P" first="Ping-Fang" last="Huang">Ping-Fang Huang</name>
</author>
<author><name sortKey="Chen, Xin" sort="Chen, Xin" uniqKey="Chen X" first="Xin" last="Chen">Xin Chen</name>
</author>
<author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
</author>
</analytic>
<series><title level="j">FEBS letters</title>
<idno type="ISSN">0014-5793</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Cysteine Endopeptidases</term>
<term>Endopeptidases</term>
<term>Metals (chemistry)</term>
<term>Molecular Sequence Data</term>
<term>Protease Inhibitors (chemistry)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>SARS Virus (enzymology)</term>
<term>Vero Cells</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Metals</term>
<term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Cysteine Endopeptidases</term>
<term>Endopeptidases</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Molecular Sequence Data</term>
<term>Vero Cells</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">3C-like (3CL) protease is essential for the life cycle of severe acute respiratory syndrome-coronavirus (SARS-CoV) and therefore represents a key anti-viral target. A compound library consisting of 960 commercially available drugs and biologically active substances was screened for inhibition of SARS-CoV 3CL protease. Potent inhibition was achieved using the mercury-containing compounds thimerosal and phenylmercuric acetate, as well as hexachlorophene. As well, 1-10 microM of each compound inhibited viral replication in Vero E6 cell culture. Detailed mechanism studies using a fluorescence-based protease assay demonstrated that the three compounds acted as competitive inhibitors (Ki=0.7, 2.4, and 13.7 microM for phenylmercuric acetate, thimerosal, and hexachlorophene, respectively). A panel of metal ions including Zn2+ and its conjugates were then evaluated for their anti-3CL protease activities. Inhibition was more pronounced using a zinc-conjugated compound (1-hydroxypyridine-2-thione zinc; Ki=0.17 microM) than using the ion alone (Ki=1.1 microM).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15358550</PMID>
<DateCompleted><Year>2004</Year>
<Month>11</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0014-5793</ISSN>
<JournalIssue CitedMedium="Print"><Volume>574</Volume>
<Issue>1-3</Issue>
<PubDate><Year>2004</Year>
<Month>Sep</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV.</ArticleTitle>
<Pagination><MedlinePgn>116-20</MedlinePgn>
</Pagination>
<Abstract><AbstractText>3C-like (3CL) protease is essential for the life cycle of severe acute respiratory syndrome-coronavirus (SARS-CoV) and therefore represents a key anti-viral target. A compound library consisting of 960 commercially available drugs and biologically active substances was screened for inhibition of SARS-CoV 3CL protease. Potent inhibition was achieved using the mercury-containing compounds thimerosal and phenylmercuric acetate, as well as hexachlorophene. As well, 1-10 microM of each compound inhibited viral replication in Vero E6 cell culture. Detailed mechanism studies using a fluorescence-based protease assay demonstrated that the three compounds acted as competitive inhibitors (Ki=0.7, 2.4, and 13.7 microM for phenylmercuric acetate, thimerosal, and hexachlorophene, respectively). A panel of metal ions including Zn2+ and its conjugates were then evaluated for their anti-3CL protease activities. Inhibition was more pronounced using a zinc-conjugated compound (1-hydroxypyridine-2-thione zinc; Ki=0.17 microM) than using the ion alone (Ki=1.1 microM).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsu</LastName>
<ForeName>John T-A</ForeName>
<Initials>JT</Initials>
<AffiliationInfo><Affiliation>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, National Defense Medical Center, Taipei 115, Taiwan, ROC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kuo</LastName>
<ForeName>Chih-Jung</ForeName>
<Initials>CJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hsieh</LastName>
<ForeName>Hsing-Pang</ForeName>
<Initials>HP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yeau-Ching</ForeName>
<Initials>YC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Huang</LastName>
<ForeName>Kuo-Kuei</ForeName>
<Initials>KK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lin</LastName>
<ForeName>Coney P-C</ForeName>
<Initials>CP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Huang</LastName>
<ForeName>Ping-Fang</ForeName>
<Initials>PF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Xin</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liang</LastName>
<ForeName>Po-Huang</ForeName>
<Initials>PH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008670">Metals</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008670" MajorTopicYN="N">Metals</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year>
<Month>05</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2004</Year>
<Month>08</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2004</Year>
<Month>08</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>9</Month>
<Day>11</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>11</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>9</Month>
<Day>11</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15358550</ArticleId>
<ArticleId IdType="doi">10.1016/j.febslet.2004.08.015</ArticleId>
<ArticleId IdType="pii">S0014579304010087</ArticleId>
<ArticleId IdType="pmc">PMC7134601</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem. 2004 May 15;12(10):2517-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15110833</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 16;279(3):1637-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14561748</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cancer Commun. 1991 Jul;3(7):207-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1867954</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochemistry. 2004 May 4;43(17):4906-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15109248</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hepatology. 2000 Feb;31(2):364-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10655259</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>EMBO J. 2002 Jul 1;21(13):3213-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12093723</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2003 Nov 17;13(22):3989-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592491</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2004 Sep 10;574(1-3):116-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15358550</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>QJM. 2003 Jan;96(1):35-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12509647</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 11;318(4):862-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15147951</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15226499</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biomed Sci. 2004 Jan-Feb;11(1):117-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14730215</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem J. 1999 Oct 1;343 Pt 1:29-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10493908</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Res Commun Chem Pathol Pharmacol. 1989 Dec;66(3):425-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2558406</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15215127</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 1974 Apr 12;248(449):588-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4363085</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002B60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:15358550 |texte= Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15358550" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |